HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Wuhan Dazhong Dental Medical - Valuation Performance May Disappoint Investors

Pre-IPO Hanx Biopharmaceuticals - The Risk of Pipeline Development Failure Is High

Pre-IPO VISEN Pharmaceuticals - The Product Pipeline and the Key Risks

Hansoh Pharmaceutical Group (3692.HK) - Successful Business Transformation Opens up Valuation Upside

Equity Capital Markets

VISEN Pharmaceuticals / Equity Capital Markets

<ul>
<li>All the three candidates lonapegsomatropin, TransCon CNP, palopegteriparatide in the pipeline of VISEN are based on Exclusive License Agreements with Ascendis Pharma. So, there're concerns about VISEN's independent R&amp;D capabilities.</li>
<li>VBP would destroy the price system of growth hormone market in China, and market size would shrink due to price reduction and decreasing demand as fewer babies will be born.</li>
<li>Post investment valuation reached US$1.03 billion. Since leading domestic companies have dominated the market, it’s not easy for VISEN to break through. Valuation of VISEN could be lower than peers.</li>
</ul>


All the three candidates lonapegsomatropin, TransCon CNP, palopegteriparatide in the pipeline of VISEN are based on Exclusive License Agreements with Ascendis Pharma. So, there're concerns about VISEN's independent R&amp;D capabilities.
VBP would destroy the price system of growth hormone market in China, and market size would shrink due to price reduction and decreasing demand as fewer babies will be born.
Post investment valuation reached US$1.03 billion. Since leading domestic companies have dominated the market, it’s not easy for VISEN to break through. Valuation of VISEN could be lower than peers.


Anhui Anke Biotechnology (Group) (300009 CH)

Pre-IPO VISEN Pharmaceuticals (PHIP Updates) - Some Points Worth the Attention